Advanced Search:
Equity Index Forex Crypto Commodity

REGN - Regeneron Pharmaceuticals

$904.70  -15.62 (-1.7%)

Updated: 03:11 May 5, 2024 EST

Next Hour's AI Forecast

97.48%

Avg. Accuracy (AI)

$978.37

Next Session's AI Forecast

96.41%

Avg. Accuracy (AI)

$947.89

Next Week's AI Forecast

83.33%

Trend's Accuracy (AI)

$921.01

Regeneron Pharmaceuticals's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

REGENERON PHARMACEUTICALS - HISTORICAL DATA 6M

  • Last price

    $ 904.70

  • Daily change

    $ -15.62

  • Previous Close

    $ 920.32

  • Last Updated

    03:11 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.14 0.14 0.03 0.15 0.1

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.14 1.06 0.8 0.83 0.9

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 100% 78.77%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
961.46 4.56% 919.5 -1.14% 930.15 3.09% 902.27

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.29 34.21 3.07 22.48

Regeneron Pharmaceuticals Technical Analysis News

Regeneron Pharmaceuticals

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 13677
Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Corporate Governance

Regeneron Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 10; Compensation: 9.

REGENERON PHARMACEUTICALS'S HOLDERS RANK

List of holders with stock participation in Regeneron Pharmaceuticals.

Holder Rank Holder Shares Date Reported % Out Value